Biotech · Private company
Kala Pharmaceuticals, Inc.
Track this companyFree. Adds Kala Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials110 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- KPI-121 0.25%Phase 3 · Ocular Infections, Irritations and InflammationsClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 0.25% Ophthalmic SuspensionPhase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 1.0%Phase 3 · Ocular Infections, Irritations and InflammationsClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 1%Phase 3 · Ocular InflammationClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 1% Ophthalmic Suspension dosed BIDPhase 3 · Post Surgical Ocular Inflammation and PainClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 Ophthalmic SuspensionPhase 3 · Kerato Conjunctivitis SiccaClinicalTrials.gov · fetched Nov 12, 2026
- Prednisolone acetatePhase 3 · Ocular InflammationClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 3 · Kerato Conjunctivitis SiccaClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle of KPI-121 0.25%Phase 3 · Ocular Infections, Irritations and InflammationsClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle of KPI-121 1.0%Phase 3 · Ocular Infections, Irritations and InflammationsClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3 · Post Surgical Ocular Inflammation and PainClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121Phase 2 · BlepharitisClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121Phase 2 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 2 · BlepharitisClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 0.25% Ophthalmic SuspensionRetinal Vein OcclusionClinicalTrials.gov · fetched Nov 12, 2026
- KPI-121 1.0% Ophthalmic SuspensionRetinal Vein OcclusionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCEDPHASE2 · TERMINATED · started Feb 7, 2023ClinicalTrials.gov NCT05727878 · fetched Nov 12, 2026
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant RejectionPHASE4 · COMPLETED · started Nov 23, 2021ClinicalTrials.gov NCT05136443 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 in Subjects With DEDPHASE3 · COMPLETED · started Jul 10, 2018ClinicalTrials.gov NCT03616899 · fetched Nov 12, 2026
- KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in ChildrenPHASE3 · TERMINATED · started Jul 3, 2018ClinicalTrials.gov NCT03596723 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02819284 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and PainPHASE3 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02793817 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseasePHASE3 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02813265 · fetched Nov 12, 2026
- Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular EdemaNA · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02245516 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland DiseasePHASE2 · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02218489 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseasePHASE2 · COMPLETED · started Jun 1, 2014ClinicalTrials.gov NCT02188160 · fetched Nov 12, 2026
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical InflammationPHASE3 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02163824 · fetched Nov 12, 2026